TW202523658A - 化合物、組合物及使用方法 - Google Patents

化合物、組合物及使用方法 Download PDF

Info

Publication number
TW202523658A
TW202523658A TW113132645A TW113132645A TW202523658A TW 202523658 A TW202523658 A TW 202523658A TW 113132645 A TW113132645 A TW 113132645A TW 113132645 A TW113132645 A TW 113132645A TW 202523658 A TW202523658 A TW 202523658A
Authority
TW
Taiwan
Prior art keywords
compound
mmol
piperidine
alkyl
mixture
Prior art date
Application number
TW113132645A
Other languages
English (en)
Chinese (zh)
Inventor
愛倫 泰勒 霍普
史蒂芬 米施克
丹尼爾 拉
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW202523658A publication Critical patent/TW202523658A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW113132645A 2019-05-24 2020-05-22 化合物、組合物及使用方法 TW202523658A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962852565P 2019-05-24 2019-05-24
US62/852,565 2019-05-24

Publications (1)

Publication Number Publication Date
TW202523658A true TW202523658A (zh) 2025-06-16

Family

ID=71078654

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113132645A TW202523658A (zh) 2019-05-24 2020-05-22 化合物、組合物及使用方法
TW109117233A TWI855081B (zh) 2019-05-24 2020-05-22 化合物、組合物及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109117233A TWI855081B (zh) 2019-05-24 2020-05-22 化合物、組合物及使用方法

Country Status (7)

Country Link
US (1) US20220332699A1 (https=)
EP (1) EP3976186A1 (https=)
JP (2) JP7687964B2 (https=)
AR (1) AR119010A1 (https=)
MA (1) MA56032A (https=)
TW (2) TW202523658A (https=)
WO (1) WO2020243027A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
IL309208A (en) 2021-06-11 2024-02-01 Sage Therapeutics Inc Neuroactive steroid for the treatment of alzheimer's disease
CN113501787A (zh) * 2021-08-20 2021-10-15 黑龙江省科学院石油化学研究院 一种合成6-三氟甲基-3-甲基吲唑的方法
US20240189312A1 (en) * 2022-12-02 2024-06-13 Morehouse School Of Medicine Composition for treating acute brain injury or neurodegenerative disease, method of making, and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US20100152160A1 (en) * 2008-12-12 2010-06-17 Khamrai Uttam Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
US8642621B2 (en) * 2009-09-16 2014-02-04 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
AU2011247116B2 (en) * 2010-04-29 2015-12-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1H - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -HSD1
AP2014007606A0 (en) * 2011-10-07 2014-05-31 Takeda Pharmaceutical 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
HUE039922T2 (hu) 2012-12-11 2019-02-28 Takeda Pharmaceuticals Co Heterociklusos vegyületek
EP2982666B1 (en) * 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
MX2022003845A (es) * 2019-09-30 2022-06-22 Actinogen Medical Ltd Tratamientos cognitivos medicinales.

Also Published As

Publication number Publication date
TWI855081B (zh) 2024-09-11
AR119010A1 (es) 2021-11-17
US20220332699A1 (en) 2022-10-20
MA56032A (fr) 2022-04-06
WO2020243027A1 (en) 2020-12-03
TW202110824A (zh) 2021-03-16
JP2022533436A (ja) 2022-07-22
JP7687964B2 (ja) 2025-06-03
EP3976186A1 (en) 2022-04-06
JP2025090698A (ja) 2025-06-17

Similar Documents

Publication Publication Date Title
TWI855081B (zh) 化合物、組合物及使用方法
EP4069691B1 (en) Substituted tetrahydrofurans as modulators of sodium channels
TWI756482B (zh) 治療活性化合物及其使用方法
DK2922850T3 (en) Compounds and Methods for Their Use
TWI911340B (zh) 雜芳基甲醯胺化合物
JP2026048719A (ja) Ｔｒｐｍｌモジュレーター
JP6081354B2 (ja) 治療活性組成物およびそれらの使用方法
JP6931003B2 (ja) キノリン−２−オン誘導体
BR112020025642A2 (pt) compostos heterocíclicos como inibidores da monoacilglicerol lipase
CA2850394A1 (en) Indazole compounds as kinase inhibitors and method of treating cancer with same
CA2988209A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
AU2020204341A1 (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
KR20240038996A (ko) 코로나바이러스 관련 질환의 치료를 위한 화합물 및 조성물
SG192939A1 (en) PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR
US20230312522A1 (en) Cyp46a1 inhibitors and methods of use thereof
WO2023122778A1 (en) Pyridazinone derivatives useful as t cell activators
EP3010916B1 (en) 1,3-diaminocyclopentane carboxamide derivatives
KR102528255B1 (ko) 디아실글리세롤 아실트랜스퍼라제 2 억제제로서 유용한 신규 아미노 아릴 유도체 및 이의 용도
RU2799819C1 (ru) Новое аминоарильное производное, пригодное в качестве ингибитора диацилглицеролацилтрансферазы 2, и его применение
TW202611041A (zh) 化合物、組合物及其方法
OA21241A (en) Substituted tetrahydrofurans as modulators of sodium channels.
CN117715898A (zh) 六元芳基或杂芳基酰胺类化合物及其组合物和用途
EA038455B1 (ru) Новые производные нафтиридинона и их применение в лечении аритмии